Search

everythinglearnresearchcommunity

for

Search:↓

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

The conversation discusses a patent for using topical resveratrol and melatonin to treat androgenetic alopecia (AGA) and also mentions interest in topical sulforaphane as a treatment.

Hair loss treatments like finasteride, dutasteride, minoxidil, and RU58841. Users discuss "DHT itch" at receding hairlines and suggest using dutasteride or ketoconazole shampoo for relief.

The conversation humorously discusses various hair loss treatments and options, including Minoxidil, finasteride, RU58841, biotin, ketoconazole, saw palmetto, dutasteride, and nutrition. It also mentions hair extensions and hairstyling as methods to achieve desired hairstyles.

A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

The user is experiencing a greasy and dandruff-prone scalp from using RU58841 with glycerin and is seeking alternative carriers for seborrheic dermatitis. They are also using dutasteride 0.5mg.

User got a hair system after hair transplant and finasteride didn't meet their needs. Hair system cost $200, initial install $150, and user is satisfied with the results.

The conversation is about using distilled water as a solvent for topical finasteride to reduce systemic absorption. The user is considering avoiding ethanol and propylene glycol to achieve this.

A user recently started using nanoxidil 5% for hair loss, particularly on the hairline, and is seeking feedback or experiences from others. The conversation focuses on the effectiveness of nanoxidil.

A 24-year-old is considering a hair transplant but is hesitant due to cost and finding his shaved head looks better than expected. He plans to try finasteride to improve hair density after unsuccessful attempts with minoxidil and dutasteride.

A 24-year-old male experienced significant hair regrowth after 14 months of treatment with 0.5mg dutasteride and 5mg minoxidil, with no side effects reported. He plans to consider a hair transplant for his hairline, as the treatment did not improve that area.

People are discussing the group buy and availability of KX-826 for hair loss treatment, with shipments expected around March-April. There is interest in finding more information and joining future group buys.

The user is considering switching from finasteride to dutasteride for hair loss. They are unsure if GT20029 can regrow hair, particularly on the temples. Another user mentions that regrowth on finasteride can take up to 2 years.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Bayer dismissed HMI-115 due to focus shift away from women's health.

The conversation is about someone wanting to import RU58841 or CB-03-01 from China for hair loss treatment but being concerned about receiving counterfeit products. Specific treatments mentioned are RU58841 and CB-03-01.

JeremySoCa's DHT level was 29 ng/dl, considered low, and Estradiol was 26.1 pg/dl within the normal range. They are using topical finasteride for hair loss and had a thyroidectomy due to Graves' disease.

Hair loss treatments like Dutasteride, RU58841, and Minoxidil may not work for everyone, as some individuals experience no improvement despite extensive use and research. Genetic factors can play a significant role, and standard treatments may not be effective for all.

A 15% discount is offered on hair research products like RU58841 and TEMPOL at Chemyo.com. The legality of selling these compounds is confirmed by the seller.

Dr. Bloxham's 9-month update on FUT scar revision with Verteporfin shows promising results. Excitement is high for FUE, which appears highly effective based on Dr. Barghouthi's findings.

CRISPR treatments for blood disorders have been approved, leading to discussions about its potential for treating hair loss (AGA). A study showed that editing a gene related to DHT sensitivity could lead to hair regrowth, suggesting CRISPR may eventually be used for AGA, but it's expected to be expensive and not soon available.

A new topical medication, Clascoterone, shows promise for hair loss, improving hair count significantly. Trials for Breezula are ending, but sign-ups for PP405 trials are available for 2026.

A 22-year-old male uses dutasteride, a serum with 10% minoxidil and 0.5% finasteride, and microneedling for diffuse androgenetic alopecia. Progress pictures show changes from July 2025 to February 2026.

Considering a switch from finasteride to dutasteride for hair loss treatment, and the use of minoxidil as a last resort due to its effects on hair texture.

The conversation is about the availability of hair loss treatments Breezula, SM04554, Follica FOL-004, and Follicum FOL-005 in Canada after FDA approval, including potential delays, loopholes for obtaining them, and insurance coverage.

A 28-year-old male stopped hair loss and thickened his hair using oral dutasteride and oral minoxidil after topical treatments failed. He experienced no side effects and recommends these oral treatments for others struggling with hair loss.

Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.

A new technique developed by scientists in Japan to reverse balding using hair follicle cell transplants, and the discussion around the effectiveness of this approach compared to other treatments such as Minoxidil, finasteride, RU58841, Replicel, and Hairclone.

The user is frustrated with hair loss, having switched from topical minoxidil and finasteride to dutasteride and oral minoxidil without seeing improvements. They are considering a hair transplant and are advised to continue the current treatment and explore therapy or lifestyle changes.

The conversation discusses disappointment in Verteporfin for hair loss treatment, with a mention of an upcoming trial by Dr. Bisanga. No specific treatments were confirmed as used by the original poster.